Management of recurrent cervical cancer: A review of the literature

被引:154
作者
Peiretti, M. [2 ]
Zapardiel, I. [1 ]
Zanagnolo, V. [2 ]
Landoni, F. [2 ]
Morrow, C. P. [3 ]
Maggioni, A. [2 ]
机构
[1] La Paz Univ Hosp, Dept Gynecol Oncol, Madrid 28046, Spain
[2] European Inst Oncol, Dept Gynecol Oncol, Milan, Italy
[3] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA
来源
SURGICAL ONCOLOGY-OXFORD | 2012年 / 21卷 / 02期
关键词
Cervical cancer treatment; Radiation therapy; Chemotherapy; Pelvic exenteration; GYNECOLOGIC-ONCOLOGY-GROUP; SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; EXTENDED ENDOPELVIC RESECTION; RADICAL HYSTERECTOMY; RADIATION-THERAPY; UTERINE CERVIX; PELVIC EXENTERATION; COMBINATION THERAPY; STAGE IVB;
D O I
10.1016/j.suronc.2011.12.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this narrative review is to update the current knowledge on the treatment of recurrent cervical cancer based on a literature review. Material and methods: A web based search in Medline and CancerLit databases has been carried out on recurrent cervical cancer management and treatment. All relevant information has been collected and analyzed, prioritizing randomized clinical trials. Results: Cervical cancer still represents a significant problem for public health with an annual incidence of about half a million new cases worldwide. Percentages of pelvic recurrences fluctuate from 10% to 74% depending on different risk factors. Accordingly to the literature, it is suggested that chemoradiation treatment (containing cisplatin and/or taxanes) could represent the treatment of choice for locoregional recurrences of cervical cancer after radical surgery. Pelvic exenteration is usually indicated for selected cases of central recurrence of cervical cancer after primary or adjuvant radiation and chemotherapy with bladder and/or rectum infiltration neither extended to the pelvic side walls nor showing any signs of extrapelvic spread of disease. Laterally extended endopelvic resection (LEER) for the treatment of those patients with a locally advanced disease or with a recurrence affecting the pelvic wall has been described. Conclusions: The treatment of recurrences of cervical carcinoma consists of surgery, and of radiation and chemotherapy, or the combination of different modalities taking into consideration the type of primary therapy, the site of recurrence, the disease-free interval, the patient symptoms, performance status, and the degree to which any given treatment might be beneficial. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:E59 / E66
页数:8
相关论文
共 72 条
  • [1] Bazhenov A. G., 2009, Voprosy Onkologii (St. Petersburg), V55, P319
  • [2] RANDOMIZED TRIAL OF 3 CISPLATIN DOSE SCHEDULES IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    BONOMI, P
    BLESSING, JA
    STEHMAN, FB
    DISAIA, PJ
    WALTON, L
    MAJOR, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) : 1079 - 1085
  • [3] BRICKER EM, 1950, SURG CLIN N AM, V30, P1511
  • [4] BRUNSCHWIG A, 1948, B NEW YORK ACAD MED, V24, P672
  • [5] Burghardt F., 1993, SURG GYNECOLOGIC ONC
  • [6] Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study
    Cella, David
    Huang, Helen Q.
    Monk, Bradley J.
    Wenzel, Lari
    Benda, Jo
    McMeekin, D. Scott
    Cohn, David
    Ramondetta, Lois
    Boardman, Cecelia H.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 119 (03) : 531 - 537
  • [7] Cerrotta A, 2002, EUR J GYNAECOL ONCOL, V23, P115
  • [8] Ileal orthotopic neobladder after pelvic exenteration for cervical cancer
    Chiva, Luis M.
    Lapuente, Fernando
    Nunez, Carlos
    Ramirez, Pedro T.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 113 (01) : 47 - 51
  • [9] RADICAL HYSTERECTOMY FOR RECURRENT CARCINOMA OF THE UTERINE CERVIX AFTER RADIOTHERAPY
    COLEMAN, RL
    KEENEY, ED
    FREEDMAN, RS
    BURKE, TW
    EIFEL, PJ
    RUTLEDGE, FN
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 55 (01) : 29 - 35
  • [10] del Carmen M G, 2000, Oncologist, V5, P18, DOI 10.1634/theoncologist.5-1-18